Log In
BCIQ
Print this Print this
 

NKTR-119

  Manage Alerts
Collapse Summary General Information
Company Nektar Therapeutics
DescriptionCo-formulation of oral naloxegol (NKTR-118) and an opioid analgesic
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPreclinical
Standard IndicationPain
Indication DetailsTreat pain
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,505.0M

$125.0M

$1,380.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/28/2009

$1,505.0M

$125.0M

$1,380.0M

Get a free BioCentury trial today